Argos Therapeutics Inc., a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, raised additional $17.5m in Series E financing.
This brought the total amount of committed funds from $42.5m to $60m. In August 2013, Argos announced the closing of a $42.5m Series E financing (read here).
Backers included current investors (Pharmstandard International S.A., Green Cross Corporation, Forbion Capital, TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement de Quebec, Morningside Group and Aurora Funds) and one new investor.
The funds will be used to support the company’s ongoing ADAPT pivotal Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).
Led by Jeff Abbey, president and chief executive officer, Argos has developed Arcelis™, a personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient’s disease and is potentially applicable to a wide range of different cancers and infectious diseases.
The company’s most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC. It recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV.